Keytruda Inj and Opdivo Inj approved promptly for off-label use
The Health Insurance Review & Assessment Service(President Seung-Taek Kim, HIRA) decided to approve off-label uses of Keytruda Inj(generic name: pembrolizumab) and Opdivo Inj(generic name: nivolumab), immune checkpoint inhibitors applied to medical institutes at the Multidisciplinary Committee, a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
